Physician profile
Abdul H Khan
NPI 1922129774
$3,605.04
in general payments reported to CMS, 2019-2025
27 companies · $1,619 in 2025
The $1,619 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $114 · 2021: $285 · 2022: $503 · 2023: $523 · 2024: $561 · 2025: $1,619.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,703.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,703.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $591.56 | 2022-2025 | |
| Madrigal Pharmaceuticals | $471.05 | 2025 | Rezdiffra |
| Celgene Corporation | $355.48 | 2022-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $352.76 | 2024-2025 | Entyvio |
| Janssen Biotech, INC. | $222.23 | 2022-2025 | Tremfya, Stelara |
| Astrazeneca Pharmaceuticals LP | $194.06 | 2022-2024 | Andexxa |
| Boston Scientific Corporation | $180.88 | 2021 | |
| Genzyme Corporation | $176.67 | 2022-2025 | |
| Endogastric Solutions, INC | $154.07 | 2024 | Esophyx |
| Ethicon US, LLC | $114.25 | 2019 | |
| Acacia Pharma INC | $103.90 | 2021 | |
| Aimmune Therapeutics, INC. | $99.63 | 2025 | Zenpep, Vowst |
| Conmed Corporation | $95.71 | 2023-2025 | Conmed Biliary, Airseal |
| Qol Medical, LLC | $74.91 | 2022-2023 | Sucraid |
| Davol INC. | $62.50 | 2023 | Arista Ah Flexitip |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $60.54 | 2022-2023 | Talicia, Aemcolo, Movantik |
| Evoke Pharma, INC. | $56.30 | 2024 | |
| Medtronic, INC. | $55.18 | 2022-2023 | Bravo |
| Echosens North America, INC. | $35.86 | 2025 | Fibroscan |
| Phathom Pharmaceuticals, INC. | $22.50 | 2025 | Voquezna |
| Daiichi Sankyo INC. | $21.65 | 2022 | |
| Alcresta Therapeutics, INC. | $19.22 | 2023 | Relizorb |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.87 | 2022 | |
| Olympus America INC. | $18.81 | 2022 | |
| Nestle Healthcare Nutrition INC. | $17.70 | 2023 | |
| Shield Therapeutics INC | $14.88 | 2025 | |
| Celltrion USA INC. | $13.87 | 2024 | Zymfentra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdul Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.